Market Newsdesk

LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Zosano
Pharma Corporation (NASDAQ: ZSAN)
Class Period:   February 13, 2017 – September 30, 2020
Lead Plaintiff Deadline: December 28, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) that pharmocokinetic studies submitted in connection with the Company’s NDA included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) that, as a result of the foregoing differences among patient results, the FDA was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) that, as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

Wells Fargo & Company (NYSE: WFC)
Class Period: October 13, 2017 – October 13, 2020
Lead Plaintiff Deadline: December 29, 2020

Shareholders with $50,000 losses or more are encouraged to contact the firm

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Wells Fargo had systematically failed to follow appropriate underwriting standards and due diligence guidelines in issuing billions of dollars’ worth of commercial loans, including by inflating the net income and future expected cash flows of its commercial clients to justify issuing excessive loan amounts; (2) a materially higher proportion of Wells Fargo’s commercial loans were to customers of poor credit quality and/or at a substantially higher risk of default than disclosed to investors; (3) Wells Fargo had failed to timely write down commercial loans, CLOs and CMBS on its books that had suffered impairments; (4) Wells Fargo had materially understated the reserves needed for expected credit losses in its commercial portfolios; (5) Wells Fargo had systematically misrepresented the credit quality and likelihood of default of the loans it packaged and securitized into CLOs and CMBS, including by artificially inflating the net income and expected cash flows of its commercial clients in loan and securitization documentation; (6) the CLO and CMBS-related loans issued and investment securities held by Wells Fargo were of lower credit quality and worth far less than represented to investors; (7) as a result of the foregoing, the Company’s statements regarding the credit quality of its commercial loans, its underwriting and due diligence practices, and the value of its CLO and CMBS books were materially false and misleading; and (8) as a result of the foregoing, the Company was exposed to severe undisclosed risks of financial, reputational and legal harm, in particular in the event of significant and sustained stress in the commercial credit markets.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Loop Industries, Inc. (NASDAQ: LOOP)
Class Period:  September 24, 2018 – October 12, 2020
Lead Plaintiff Deadline:  December 14, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loop’s purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loop’s announced partnerships with Indorama and Thyssenkrupp; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Turquoise Hill Resources Ltd. (NYSE: TRQ)
Class Period:  July 17, 2018 – July 31, 2019
Lead Plaintiff Deadline:  December 14, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the progress of underground development of Oyu Tolgoi was not proceeding as planned; (2) that there were significant undisclosed underground stability problems that called into question the design of the mine and the projected cost and timing of production; (3) the Company’s publicly released estimates of the cost, date of completion, and dates for production from the underground mine were not realizable; (4) the development capital required for the underground development of Oyu Tolgoi would cost significantly more than a billion dollars over what Turquoise Hill had represented; (5) the Company would require further financing and/or equity to complete the project; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Evolus, Inc. (NASDAQ: EOLS)
Class Period:  February 1, 2019 – July 6, 2020
Lead Plaintiff Deadline:  December 15, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the real source of botulinum toxin bacterial strain, along with the manufacturing processes used to develop Jeuveau, originated with and were misappropriated from Medytox; (2) that sufficient evidentiary support existed for the allegations that the Company misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau; (3) as a result, the Company faced a real threat of regulatory and/or court action, barring the import, marketing, and sale of Jeuveau; (4) which in turn seriously threatened Evolus’ ability to commercialize Jeuveau in the United States and generate revenue; and (5) that any revenues generated from the sale of Jeuveau were based on Evolus’ unlawful actions, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox; and (6) that, as a result, the Company’s public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.  If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

LOS ANGELES, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) — Today, Digital Domain announces “Douglas,” the most realistic real-time autonomous digital human in the world. Currently in development, Douglas was designed to break down the barriers in human-to-machine interactions, yielding conversations that feel natural and easy. With unmatched facial realism, Douglas is chameleon-like in its ability to switch faces, providing future customers with even more flexibility when it hits the market in 2021.

“Everywhere you look you see virtual assistants, chatbots and other forms of AI-based communication interacting with people,” said Darren Hendler, director of Digital Humans Group at Digital Domain. “As companies decide to expand past voice-only interactions, there’s going to be a real need for photorealistic humans that behave in the ways we expect them to. That’s where Douglas comes in.”

Douglas uses numerous types of machine learning and Digital Domain R&D to reproduce the most common mannerisms people expect to see in a lifelike digital human. By focusing on language processing, expressions, vision tracking and more, Douglas can do everything from leading conversations to remembering people. And because Douglas’ response rate is currently the same as Alexa and Siri, these conversations have a natural flow, removing the long pauses that slow other autonomous digital humans down.

While perfect for any project that requires facial realism, Douglas will be especially helpful to companies who need an avatar to answer questions or help customers with repetitive tasks. The current version can already connect to any chatbot or assistant system, bringing a friendly face and an emotionally intelligent response to real-time interactions. Once finished, this technology can be easily deployed online, in meeting platforms or in kiosks around the globe.

Douglas is the latest technology built off the likeness of Senior Director of Software R&D, Dr. Doug Roble, which has already led to several advancements in both real-time digital humans and AI facial capture. By comparing Douglas to the real-life Roble, Digital Domain has been able to advance the realism of their design as they prepare the technology for wider use.

To create Douglas, Roble submitted to over a hundred hours of performance capture, including a live book reading that logged his voice and expressions. A neural rendering tool was also trained by taking photos of Roble in a variety of lighting conditions. From this data, the tool can now deliver levels of realism that would have been impossible to achieve before with traditional techniques, including replicating the mannerisms of another person with only few expressions. In recent months, the team has begun swapping out faces and trying on new voices, an edit that only requires 30 minutes of audio or 10 minutes of video.

“Douglas has introduced a level of realism unseen before in the autonomous human world, even before it comes to market,” said Daniel Seah, chief executive officer of Digital Domain. “As Digital Domain continues to expand our R&D into facial capture and autonomous behavior, we’ll be able to extend these innovations out to consumers and tech partners who are looking to enhance virtual human capabilities beyond simple voice recognition applications.”

Digital Domain is scheduling demos now and is interested in all opportunities around Douglas including investments, partnerships and client work. To schedule a call (or talk to Douglas), please contact: [email protected].

To see Douglas in action, click here.

About Digital Domain
Digital Domain creates transportive experiences that entertain, inform and inspire. Throughout the last quarter of a century, the studio has grown to lead the visual effects industry, expanding globally into digital humans, virtual production, previsualization and virtual reality, and adding commercials, game cinematics and episodics to the robust film roster. Digital Domain’s rich legacy consists of hundreds of blockbuster feature films for every major studio and thousands of commercials, music videos, game cinematics and digital content by world-renowned directors and brands.

A creative force in visual effects and premium content, Digital Domain have brought artistry and technology to films including Titanic, The Curious Case of Benjamin Button and blockbusters Ready Player One, Avengers: Infinity War and Avengers: Endgame. Staff artists have won more than 100 major awards, including Academy Awards, Clios, BAFTA awards and Cannes Lions.

Digital Domain has successfully become the first independent visual effects studio to enter Greater China. In 2018, Digital Domain acquired one of China’s VR hardware equipment pioneers and leaders – VR Technology Holdings Ltd, Shenzhen（“3Glasses”).

Digital Domain has locations in Los Angeles, Vancouver, Montreal, Beijing, Shanghai, Shenzhen, Hong Kong, Taipei and Hyderabad. Digital Domain Holdings Limited is listed on the Hong Kong Stock Exchange (stock code: 547).

Digital Domain: www.digitaldomain.com

Attachment

• DHG_dougLaptop_v001 (1)